Table 1.
Patient number | Age (years) | Eye | Sex | Clinical setting | Initial BCVA | Hypopyon | IOP | Initial Tx | Initial intravitreal injections | Additional Tx (days after initial Tx) | Last BCVA | Follow-up time (months) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 72 | OD | F | Post-ECCE surgery (3 weeks) | HM | Yes | 6 | PPV | VANC + GENT + CFX | None | 20/200 | 5 |
2 | 10 | OD | M | Penetrating trauma (tree branch) | LP | No | UKN | PPV | VANC + CFT | None | 20/400 | 52 |
3 | 14 | OS | M | Penetrating trauma (rock) | LP | No | 23 | T + I | VANC + CFT | PPV, VANC + GENT (1) | NLP | 2 |
Abbreviations: BCVA, best-corrected visual acuity; CFT, ceftazidime (2.25 mg/0.1 mL); CFX, ceftriaxone (2 mg/0.1 mL); ECCE, extracapsular cataract extraction; F, female; GENT, gentamicin (200 μg/0.1 mL); HM, hand motion; IOP, intraocular pressure; LP, light perception; M, male; NLP, no light perception; OD, right eye; OS, left eye; PPV, pars plana vitrectomy; T + I, tap and injection; Tx, treatment; UKN, unknown; VANC, vancomycin (1 mg/0.1 mL).